TuHURA Biosciences, Inc. (HURA): Operating Cash Flow
-$27.63M
Year ended 2025-12-31
-$29.69M
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$27.63M | n/m | 2026-03-31, From 2025-01-01 |
| 2024-12-31 | -$14.73M | n/m | 2026-03-31, From 2024-01-01 |
| 2023-12-31 | -$11.95M | n/a | 2025-03-31, From 2023-01-01 |
| No annual figure between 2022-06-30 and 2023-12-31. | |||
| 2022-06-30 | -$20.39M | n/m | 2023-09-18, From 2021-07-01 |
| 2021-06-30 | -$18.86M | n/m | 2022-09-27, From 2020-07-01 |
| 2020-06-30 | -$7.93M | n/m | 2021-09-28, From 2019-07-01 |
| 2019-06-30 | -$6.33M | n/m | 2020-09-18, From 2018-07-01 |
| 2018-06-30 | -$9.85M | n/m | 2019-09-09, From 2017-07-01 |
| 2017-06-30 | -$8.02M | n/m | 2018-09-24, From 2016-07-01 |
| 2016-06-30 | -$5.15M | n/m | 2016-09-13, From 2015-07-01 |
| 2015-06-30 | -$3.85M | n/m | 2016-09-13, From 2014-07-01 |
| 2014-06-30 | -$4.00M | n/a | 2015-11-16, From 2013-07-01 |
| No annual figure between 2012-12-31 and 2014-06-30. | |||
| 2012-12-31 | -$578.0K | n/m | 2014-08-28, From 2012-01-01 |
| 2011-12-31 | -$228.7K | n/a | 2014-03-10, From 2011-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| TuHURA Biosciences, Inc. (HURA) | 2025-12-31 | -$27.63M | n/m |
| Abbott Laboratories (ABT) | 2025-12-31 | $9.57B | +11.8% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $14.16B | -6.8% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $2.45M | +109.7% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $16.81B | +90.7% |
| Pfizer Inc (PFE) | 2025-12-31 | $11.70B | -8.2% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $24.53B | +1.1% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $35.32M | +39.6% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $16.47B | -23.3% |
Compare HURA, ABT, BMY, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗